aripiprazole (VS-101) / VSPharmTech - LARVOL DELTA

VSPharmtech, Radiosensitizer ’VS-101’ Glioblastoma Phase 2 FDA Approval [Google translation] (HIT News) - "VS PharmTech (CEO Park Shin-young) announced on the 20th that it received IND approval from the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial plan for glioblastoma (GBM) for its radiosensitizer candidate substance 'VS-101'....According to the company, this phase 2 clinical trial for glioblastoma will be conducted by comparing two experimental groups that added VS-101 (2 mg, 5 mg) to the standard treatment of radiation therapy and 'temozolomide' combination therapy, and a control group that did not include VS-101, to evaluate the therapeutic efficacy and safety."

IND • Glioblastoma